Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase Ib/II Trial of Combining Pembrolizumab and Lenvatinib With Stereotactic Body Radiotherapy for Hepatocellular Carcinoma Patients With Portal Vein Thrombosis.

NCT05286320 is registered in ClinicalTrials.gov with National Taiwan University Hospital as lead sponsor.

NCT NCT05286320
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05286320 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase Ib/II Trial of Combining Pembrolizumab and Lenvatinib With Stereotactic Body Radiotherapy for Hepatocellular Carcinoma Patients With Portal Vein Thrombosis.
Lead sponsor
National Taiwan University Hospital
Phase
Phase 1/2
Overall status
Not yet recruiting
Start date
March 1, 2023
Completion date
September 30, 2026
Enrollment
27 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

lenvatinib, pembrolizumab, stereotactic body radiotherapy, unresectable hepatocellular carcinoma